Search results
Showing 106 to 120 of 173 results for leukaemia
Awaiting development Reference number: GID-TA11936 Expected publication date: TBC
Awaiting development Reference number: GID-TA11425 Expected publication date: TBC
Awaiting development Reference number: GID-TA11948 Expected publication date: TBC
Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]
Discontinued Reference number: GID-TA10494
Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]
Discontinued Reference number: GID-TAG482
This quality standard covers diagnostic reporting and the organisation of haematological cancer services for people of all ages (children, adults and young people) and managing haematological cancers in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS150Show all sections
Sections for QS150
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]
Discontinued Reference number: GID-TA10088
Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies [ID1455]
Discontinued Reference number: GID-TA10356
Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]
Discontinued Reference number: GID-TAG399
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]
Discontinued Reference number: GID-TA10081
Awaiting development Reference number: GID-TA11837 Expected publication date: TBC
Discontinued Reference number: GID-TA11181
Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)
Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Neutropenic sepsis: prevention and management in people with cancer (CG151)
This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care. It aims to reduce the risk of infection in people with neutropenia (low number of white blood cells) who are receiving anticancer treatment and improve management of neutropenic sepsis.